Rebamipide
Rebamipide is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cholecystokinin receptor type A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
53 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dry eye syndromes | D015352 | — | H04.12 | 1 | 4 | 6 | 1 | — | 12 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | 4 | 6 | 1 | — | 11 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | — | 1 | 4 | 3 | 2 | 10 |
| Ulcer | D014456 | MPATH_579 | — | 1 | 3 | 2 | 2 | 1 | 7 |
| Stomach ulcer | D013276 | — | K25 | — | 1 | 2 | 3 | 1 | 6 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 2 | 1 | 5 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 1 | 2 | 1 | — | 4 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 1 | — | 1 | 1 | 3 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | 1 | 1 | — | 2 |
| Gastrointestinal diseases | D005767 | — | — | 1 | — | — | 1 | — | 2 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Keratoconjunctivitis | D007637 | — | H16.2 | — | 2 | 2 | — | — | 4 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | 1 | 2 | — | — | 3 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 1 | 1 | — | — | 2 |
| Mucositis | D052016 | EFO_1001898 | — | — | 1 | 1 | — | — | 2 |
| Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | 1 | 1 | — | — | 1 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | 1 | 1 | — | — | 1 |
| Atrophic gastritis | D005757 | EFO_1000826 | K29.4 | — | — | 1 | — | — | 1 |
| Spondylarthritis | D025241 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | — | — | — | 1 |
| Xerostomia | D014987 | — | K11.7 | — | 1 | — | — | — | 1 |
| Behcet syndrome | D001528 | EFO_0003780 | M35.2 | 1 | 1 | — | — | — | 1 |
| Oral ulcer | D019226 | HP_0000155 | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomic testing | D000071185 | — | — | — | — | — | — | 1 | 1 |
| Therapeutic equivalency | D013810 | — | — | — | — | — | — | 1 | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
| Adenoma | D000236 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rebamipide |
| INN | rebamipide |
| Description | 2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid is a secondary carboxamide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 90098-04-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1697771 |
| ChEBI ID | — |
| PubChem CID | 5042 |
| DrugBank | DB11656 |
| UNII ID | LR583V32ZR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CCKAR
CCKAR
Organism
Homo sapiens
Gene name
CCKAR
Gene synonyms
CCKRA
NCBI Gene ID
Protein name
cholecystokinin receptor type A
Protein synonyms
CCK-A receptor, CCK-AR, CCK1-R, cholecystokinin type 1 receptor, cholecystokinin type-A receptor, Cholecystokinin-1 receptor
Uniprot ID
Mouse ortholog
Cckar (12425)
cholecystokinin receptor type A (Q9DBV6)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Rebamipide – Kubota Pharmaceutical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,578 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,018 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use